Clinical trial NCT05407142: An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)
Official title: An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers at the Age of 18-60 Years (Clinical Trials, Phase III)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Coronavirus Infections
Vaccine
Keywords: COVID-19
Coronavirus infections
Vaccine
SARS-Cov-2
Immunobiological medicine
Lead sponsor: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Sponsor class: OTHER_GOV
First posted: 2022-06-07
Enrollment: 29000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers at the Age of 18-60 Years

Detailed description: The study group is planned to screen a maximum of 32,000 volunteers inclusive, of which it is planned to include 3,500 men and women aged 18 to 60 years who meet the criteria for inclusion in the study and do not have non-inclusion criteria.

The study group consisted of 3,500 volunteers who received the CoviVac vaccine

Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).

Cohorts:

1. The data of the first 1000 volunteers of subgroup 1 will be used to assess the efficacy + safety + immunogenicity of the vaccine under study.
2. The data of the next 1100 volunteers of subgroup 1 will be used to analyze the efficacy + safety of the vaccine under study.

Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.

The data of 1400 volunteers vaccinated three times with an interval of 21 days will be used to assess the effectiveness + safety + immunogenicity of the vaccine under study

Control group - official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.

The data of the control group volunteers will be used to evaluate the effectiveness of the vaccine under study.

Eligibility criteria: Inclusion Criteria:

* Volunteers must meet the following inclusion criteria:

Type of participants \* Healthy volunteers or volunteers with a history of stable diseases that do not meet any of the criteria for non-inclusion in the study.

Age at the time of signing the Informed Consent \* from ≥ 18 to \< 60 years.

Paul \* Male or female.

The volunteers of the study group must meet the following additional inclusion criteria:

* Written Informed consent of volunteers to participate in a clinical trial.
* Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits).

  * For women capable of childbirth - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Women should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals), or be sterile, or in a postmenopausal state.
  * For men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals), or be sterile.

Exclusion Criteria:

* Volunteers cannot be included in the study if any of the following criteria are present:

SARS-CoV-2 infection

\* A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.

Diseases or medical conditions

* Severe and/or uncontrolled diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, gastrointestinal tract, liver, kidneys, hematopoietic, immune systems.
* Is registered at the dispensary for tuberculosis, leukemia, oncological diseases, autoimmune diseases.

  • Any confirmed or suspected immunosuppressive or immunodeficiency condition in the anamnesis.
* Splenectomy in the anamnesis.
* Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l) according to anamnesis.
* Anorexia.

Prior or concomitant therapy

* Vaccination with any vaccine carried out within 30 days before vaccination / the first dose of the studied vaccine or planned administration within 30 days after vaccination / the last dose of the studied vaccine.
* Prior vaccination with an experimental or registered vaccine that may affect the interpretation of the study data (any coronavirus or SARS vaccines).
* Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs (immunoregulatory peptides, cytokines, interferons, immune system effector proteins (immunoglobulins), interferon inducers (cycloferon) during the six months preceding the study, according to anamnesis.
* Treatment with glucocorticosteroids (≥ 20 mg of prednisone, or an analog, for more than 15 days during the last month).
* Volunteers who received immunoglobulin preparations or blood transfusion during the last 3 months before the start of the study according to anamnesis.

Other non-inclusion criteria

\* Pregnancy or breast-feeding. Participation in any other clinical trial within the last 3 months.

Volunteers of the study group cannot be included in the study if any of the following criteria are present:

Diseases or medical conditions

* Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
* Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.)•
* Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
* The axillary temperature at the time of vaccination is more than 37.0 ° C.
* Acute infectious diseases (recovery earlier than 4 weeks before vaccination) according to anamnesis.
* Donation of blood or plasma (in the amount of 450 ml or more) less than 2 months before inclusion in the study.

Exclusion criteria:

* Withdrawal of Informed consent by a volunteer;

  \* The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;

  • Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;

  \* The established fact of pregnancy before the second vaccination;

  \* The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;

  \* For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the Protocol that may affect the results of the study.

Primary outcomes:
measure: Efficasy assessment
timeFrame: 12 month
Secondary outcomes:
measure: Classification by severity of COVID-19
timeFrame: 12 month
measure: The proportion of study subjects who died
timeFrame: 12 month
measure: The duration of laboratory and clinically confirmed COVID-19 disease.
timeFrame: 12 month
measure: The proportion of volunteers from the total number of vaccinated / revaccinated with an increase in the level of the immune response
timeFrame: 12 month
measure: Titer of specific antibody titer ≥ 4 times baseline Specific antibody titer ≥ 4 times baseline
timeFrame: 12 month
measure: The level of γ-IFN and the subpopulation composition of T-lymphocytes.
timeFrame: 12 month
measure: Safety assessment
timeFrame: 12 month
measure: Safety assessment
timeFrame: 12 month
measure: Safety assessment
timeFrame: 12 month
Other outcomes:
Locations:
city: Kirov
country: Russian Federation
facility: Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Health of Russia
city: Krasnoyarsk
country: Russian Federation
facility: RUSAL Medical Center LLC
city: Moscow, Russia, 108819
country: Russian Federation
facility: FSBSI Chumakov FSC R&D IBP RAS
city: Moscow
country: Russian Federation
facility: FSBI NIIVS named after I.I. Mechniko
city: Moscow
country: Russian Federation
facility: GBUZ "State Design Bureau named after D.D. Pletnev DZM"
city: Moscow
country: Russian Federation
facility: "Scientific Research Institute of Occupational Medicine named after Academician N.F. Izmerov" (FGBNU "Research Institute of MT")
city: Moscow
country: Russian Federation
facility: CHUZ "Clinical Hospital "Russian Railways-Medicine" named after N.A. Semashko"
city: Moscow
country: Russian Federation
facility: Limited Liability Company "H-Clinic" (LLC "H-Clinic")
city: Moscow
country: Russian Federation
facility: JSC "Medical services" CDL named after N.A.Semashko
city: Sankt Peterburg
country: Russian Federation
facility: Mmc Sogaz Llc
Study officials:
References: